HIV
ViiV’s Dovato approved in Europe as treatment option for HIV-1
July 3, 2019Research and Development, Sales and Marketing Dovato, GSK, HIV, ViiV Healthcare, pharma
ViiV Healthcare, the specialist HIV firm majority owned by GSK, is celebrating the news that the European Commission has chosen …
Researchers use gene-editing tool CRISPR to cure mice of HIV
July 3, 2019Research and Development AIDS, HIV, Nature Communications, crispr, mice, pharma
American scientists have been able to combine a new form of antiretroviral therapy (ART) with gene editing tool CRISPR/Cas9 to …
Cases of sexually transmitted infections on the rise in England, data shows
June 5, 2019Research and Development HIV, STDs, STIs, pharma PrEP, public health
Cases of sexually transmitted infections (STIs) are on the rise, according to new data from Public Health England. There were …
KCL study could lead to improved vaccinations against STIs
May 23, 2019Research and Development HIV, HSV, STIs, herpes, immune system, std
New findings from researchers at King’s College London could lead to improved vaccinations against sexually transmitted infections (STIs). Researchers at …
Gilead CEO Daniel O’Day challenged over patents on PrEP drug Truvada
May 17, 2019Medical Communications Gilead, HIV, PrEP, Truvada, patent, pharma
On 16 May, Gilead CEO Daniel O’Day was grilled over the $1,780 price tag on PrEP drug Truvada in a …
Gilead struck anti-competitive deals to retain dominance in HIV market, lawsuit says
May 15, 2019Research and Development AIDS, BMS, Gilead, HIV, Janssen, generic drugs
Gilead Sciences struck anti-competitive deals with Janssen and Britsol-Myers Squibb in an effort to retain dominance in the market for …
Clinical trial will test long acting HIV injection
May 10, 2019Medical Communications Art, CAB, HIV, Janssen, RPV, ViiV, injectable
A long-acting, injectable HIV drug combo is to be tested in a clinical trial of 350 volunteers with HIV. The …
Gilead will give 11 years’ worth of PrEP drugs to those at risk of HIV after ‘discussions’ with Trump
May 10, 2019Medical Communications Gilead, HIV, PrEP, Trump, Truvada, descovy
Gilead Sciences has agreed to donate 11 years’ worth PrEP drugs for up to 200,000 individuals each year, following “discussions …
HIV cannot be transmitted when viral load is undetectable, study shows
May 3, 2019Medical Communications Art, HIV, U=U, anti-retroviral drugs, infectious diseases, pharma
The risk of transmitting HIV through gay sex when the infected partner’s HIV load has been fully supressed by antiretroviral …
Top Ten most popular articles on Pharmafile.com this week!
April 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Genentech, Gilead, HIV, MS, Novartis, kidney disease, pharma
This week was a good one for clinical trials and a bad one for employees after both Gilead and GSK …
Doctors cure ‘bubble boy syndrome’ using modified version of HIV
April 18, 2019Research and Development HIV, SCID-X1, gene therapy, immunodeficiency, immunology
Doctors at St. Jude Children’s Research Hospital have been able to treat patients with X-linked severe combined immunodeficiency (SCID-X1) – …
Janssen’s Symtuza around 90% effective in achieving undetectable HIV-1 viral loads, when used immediately following diagnosis
April 12, 2019Medical Communications HIV, Janssen, Symtuza, pharma
Janssen has lifted the curtain on data from the first Phase 3 trial investigating the efficacy of Symtuza (darunavir 800mg, …
ViiV Healthcares scores first twin-drug FDA approval for untreated HIV-1
April 9, 2019Manufacturing and Production, Research and Development GSK, HIV, ViiV Healthcare, pharma
ViiV Healthcare, the pharmaceutical firm owned by Shionogi, Pfizer and predominantly GSK, has announced its two-drug HIV regimen Dovato (dolutegravir …
Gilead accused of ripping off US taxpayers
March 28, 2019Medical Communications, Sales and Marketing CDC, Gilead, HIV, PrEP, Truvada, US government, patents
Gilead have been accused of ‘ripping off’ US taxpayers after the firm was revealed to have generated $3 billion in …
Top Ten most popular articles on Pharmafile.com this week!
March 8, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Biogen, Gilead, HIV, Novartis, Scott Gottlieb, top 10
HIV hit the headlines this week after it was announced that a British man known only as the ‘London Patient’ …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
